A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL)

Publication Date

6-1-2024

Presented At:

American Society of Clinical Oncology (ASCO) Annual Meeting

This document is currently not available here.

Share

COinS